Trial Profile
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure on Standard Heart Failure Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Recombinant human neuregulin 1-beta (Primary)
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Sponsors Zensun (Shanghai) Sci & Tech
- 13 Jan 2022 Planned number of patients changed from 1000 to 140.
- 13 Jan 2022 Planned End Date changed from 31 Dec 2021 to 20 May 2022.
- 13 Jan 2022 Planned primary completion date changed from 30 Dec 2021 to 20 Feb 2022.